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Abstract
The present comments are restricted to the role of maternal thyroid hormone on early brain develop-
ment, and are based mostly on information presently available for the human fetal brain. It emphasizes
that maternal hypothyroxinemia – defined as thyroxine (T4) concentrations that are low for the stage
of pregnancy – is potentially damaging for neurodevelopment of the fetus throughout pregnancy, but
especially so before midgestation, as the mother is then the only source of T4 for the developing brain.
Despite a highly efficient uterine–placental ‘barrier’ to their transfer, very small amounts of T4 and
triiodothyronine (T3) of maternal origin are present in the fetal compartment by 4 weeks after
conception, with T4 increasing steadily thereafter. A major proportion of T4 in fetal fluids is not
protein-bound: the ‘free’ T4 (FT4) available to fetal tissues is determined by the maternal serum T4,
and reaches concentrations known to be of biological significance in adults. Despite very low T3
and ‘free’ T3 (FT3) in fetal fluids, the T3 generated locally from T4 in the cerebral cortex reaches
adult concentrations by midgestation, and is partly bound to its nuclear receptor. Experimental results
in the rat strongly support the conclusion that thyroid hormone is already required for normal corti-
cogenesis very early in pregnancy.
The first trimester surge of maternal FT4 is proposed as a biologically relevant event controlled by the
conceptus to ensure its developing cerebral cortex is provided with the necessary amounts of substrate
for the local generation of adequate amounts of T3 for binding to its nuclear receptor. Women unable
to increase their production of T4 early in pregnancy would constitute a population at risk for neuro-
logical disabilities in their children. As mild–moderate iodine deficiency is still the most widespread
cause of maternal hypothyroxinemia in Western societies, the birth of many children with learning
disabilities may already be preventable by advising women to take iodine supplements as soon as
pregnancy starts, or earlier if possible.
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Introduction
The association between alterations of thyroid function
early after birth and neurodevelopmental disorders has
been recognized for more than a century. For many
years of the 20th century there has been, however,
less consensus regarding the stage during fetal life
when thyroid hormone becomes necessary for normal
brain development (more extensively reviewed by us in
(1–4)).This has mostly been due to opposing views
regarding the importance of maternal thyroid
hormones for the fetus. On the one hand, those who
had personal field experience of iodine-deficiency
disorders (IDDs) were convinced of its importance,
because the severity of the central nervous system
(CNS) damage of the progeny was related to the
degree of maternal thyroxine (T4) deficiency and could
only be prevented when the latter was corrected before
midgestation. On the other hand, Western-trained phys-
icians usually adhered to the idea that maternal thyroid
hormones did not play a role in early neurodevelop-
ment, an idea apparently supported by the good
results obtained with prompt treatment of congenital
hypothyroidism (CH). This success was interpreted as
proof that the developing fetal brain did not need thyroid
hormone until after birth. The idea that the maternal
thyroid hormones were of little relevance for the early
fetal brain was reinforced by the increasing evidence
of the existence of an efficient utero–placental ‘barrier’
that prevented the transfer of maternal thyroid
hormones into the fetal compartment in amounts
that could be physiologically relevant. The importance
of an adequate provision of thyroid hormones for
brain development during later phases of pregnancy
was, however, increasingly accepted when the
transfer of maternal T4 up to birth was shown in man
(5) and its possible protective role in cases of CH was
recognized (6).
Despite the increasing awareness that thyroid hor-
mone is already required for normal brain development
during fetal life, the general consensus as late as 1999
was summarized by Utiger (7): ‘Thyroid deficiency
during the latter two thirds of gestation and the first
months after delivery can result in mental retardation
and sometimes neurological deficits. Whether thyroid
hormone is needed during the first trimester is less
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certain. If it is, it must be supplied by the mother,
because none is secreted by the fetus until the middle
trimester’. The same editorial drew attention to the
many severe neurological defects found in children
born to iodine-deficient mothers that require adequate
intervention before midgestation for their prevention,
and that do not occur in untreated CH infants. In the
present contribution we will try to summarize what is
known, and what is still unknown, regarding early
fetal thyroid hormone physiology and its dependence
on the production of T4 by the mother.
Findings from experimental rat models
Much of our present knowledge regarding transfer of
thyroid hormones from the mother to the fetus and
its possible role in fetal brain development has been
prompted by previous findings in experimental animal
models, especially in rats. There is an important simi-
larity between man and rat with respect to placent-
ation, which is hemochorial in both species. There
are, however, major differences between human and
rat brain development if we take birth as the point of
reference, because the rat is born at a less mature
stage, the newborn pup being comparable to a
human fetus nearing the third trimester. Conversely,
the human newborn might be compared with a 2- to
3-week-old rat pup, but with a very important differ-
ence that is often forgotten when postnatal findings in
hypothyroid rat models are extrapolated to the third tri-
mester human CH fetus. In man development of the
fetal brain may still be protected by the transfer of
maternal T4 during a period of development when
the rat is deprived of this potential benefit, as rat milk
does not contain thyroid hormone in relevant amounts.
Valid comparisons may, however, be made by using
the onset of active fetal thyroid function (FTF) as the
milestone for comparisons. This coincides in both
species with full maturation of the pituitary portal
vessels, and occurs at E17.5-18 in the rat (with E0
being the day of conception and E21-22 the day of
birth), and at 18–20 weeks of postmenstrual age
(PMA) in man (at 16–20 weeks postconception),
with birth at 36–40 weeks PMA. Thus, most of the
comparisons between both species will be restricted
to development and maternal–fetal interrelations
before FTF, unless stated otherwise. Findings relevant
to the present topic are very briefly summarized here.
For pertinent detailed references, see Table 3 in a
previous review (1). References are mostly restricted
to more recent studies.
T4 and triiodothyronine (T3) of maternal origin are
present, albeit at very low concentrations, in very
early rat embryonic and fetal tissues, brain included,
before onset of FTF, their concentrations being directly
influenced by those in the maternal circulation,
especially those of T4. Thyroid hormone receptor (TR)
isoforms are already present in the brain at neural
tube closure and are likely to mediate biological effects
of the T3 that has been locally generated from T4 trans-
ferred from the mother. Therefore, if the mother is
hypothyroxinemic, the brain of a hypothyroid rat
fetus is T3-deficient, even if maternal and fetal T3 are
normal, because during early development, serum-
derived T3 hardly contributes to cerebral T3 (6).
Important phases of the development of the neocortex
are altered by a period of maternal hypothyroxinemia
preceding onset of FTF (8, 9), showing directly that
thyroid hormone of maternal origin is important for
neurodevelopment.
If such experimental findings were relevant for man,
they would explain why in most cases of CH there is
no permanent severe CNS damage when T4 is supplied
starting soon after birth. Most fetuses with CH have a
normal mother, supplying enough T4 to the developing
brain throughout gestation to preferentially avoid cer-
ebral T3 deficiency. As a result, the fetal brain has not
been severely damaged before birth, and its normal
development can still be achieved by prompt postnatal
treatment with T4. They would also explain the irre-
versible damage caused by an insufficient supply of T4
during early development, when the mother is the
only source of hormone to the brain. The more severe
damage would be expected to occur when both the
mother and fetus are hypothyroxinemic throughout
pregnancy, as occurs in iodine-deficient environments,
and as increasingly confirmed by case reports (1–4, 10).
Thyroid hormones and their nuclear
receptors in the human fetal brain
As already indicated, during most of the second half of
the 20th century the prevailing idea was that the early
embryo actually developed in the absence of thyroid
hormones. Supporting this conclusion was the evidence
of a placental ‘barrier’ system that drastically limited
their transfer from the mother. Recent information
has confirmed the widespread distribution, mostly of
deiodinases D2 and D3, in the utero–placental unit
and the expression of D3 in fetal epithelia (11–14).
As in experimental animals, the existence of an active
barrier, however, does not necessarily exclude that some
iodothyronines of maternal origin actually do reach
fetal tissues, and we shall briefly summarize the existing
evidence, mostly as pertaining to the brain. Most of the
experimental findings in the rat models, are being con-
firmed – and actually extended – in humans.
From conception to midgestation
Attempts to measure the very low concentrations of
iodothyronines in fetal tissues had to await the develop-
ment of adequate extraction methods that permitted
their purification and determination by sensitive and
specific RIAs. Most commercially available methods
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that have been developed for human sera are not
adequate for the very low concentrations found up to
midgestation in human fetal serum. Commercial kits
for the estimation of ‘free’ T4 (FT4) are even less ade-
quate, because of the great qualitative and quantitative
differences in the composition of T4-binding proteins
between fetal fluids and adult serum.
During the 1980s, T4 and T3 were measured in
tissue extracts from cerebral cortex, liver and lung of
8–18 week PMA human fetuses, using improved
specific and highly sensitive RIAs (15–17). In liver,
lung and heart, only T4 was found during the second
trimester, although T3 could be demonstrated at some-
what earlier ages in lung nuclear extracts. T3 was
quantified in purified extracts from human fetal brain,
however, as early as 9–10 weeks PMA, and increased
steadily up to 18 weeks PMA, despite the fact that
during this period plasma T3 was undetectable and
,10% of adult values. By midgestation the concen-
tration of T3 in the fetal brain reached 34% of adult
values, much higher than would have been inferred
from their very low circulating T3.
Another important methodological improvement was
the development of transvaginal ultrasound-guided
puncture of the embryonic cavities (Fig. 1) to obtain
samples from the fetal compartment without severing
vascular connections with the mother. This procedure,
combined with specific and sensitive RIAs, disclosed
important new information regarding fetal thyroid
hormones early in pregnancy (18). T4, T3 and reverse
T3 (rT3) were found in the first trimester coelomic
and amniotic fluids from 5.8–11 weeks PMA (3.8–9
weeks postconceptional age) (Fig. 2). The T4 concen-
trations in the coelomic fluid were positively correlated
with the maternal circulating concentrations, but
were ,1% of the maternal values. T3 was at least
10-fold lower than T4, with rT3 being clearly higher
than T4, findings that confirmed the high D3 activities
of the placental ‘barrier’ and fetal epithelia. Concen-
trations in the coelomic fluid were higher than in the
amniotic compartment. Because of the minute amounts
of the iodothyronines found in these fluids, their possible
biological significance was often questioned.
The results were essentially confirmed and extended
in a second study (19) where transvaginal ultra-
sound-guided puncture of these cavities and of fetal
blood was performed up to 17 weeks PMA. A specific
methodology was developed for the determination of
FT4. We confirmed the previous observation (18) that
T4 in fetal fluids is more than 100-fold lower than in
Figure 1 Schematic representation of the maternal–fetal unit during the 1st (A) and 2nd (B) trimesters of pregnancy. (A) The human
fetus is surrounded by two distinct fluid cavities separated from each other by a thin membrane: the inner, or amniotic cavity (AC) con-
tains the fetus and the outer, or exocoelomic cavity (ECC), separates the amniotic cavity from the placenta and contains the secondary
yolk sac (SYS). The latter is directly connected to the fetal digestive tract and circulation. The ECC is the site of important molecular
exchanges between the mother and the fetus and contains the coelomic fluid (CF) that results from an ultrafiltrate of maternal serum
with the addition of specific placental and SYS bioproducts. The ECC is a physiological liquid extension of the early placenta (P) and
acts as a reservoir for nutrients needed by the developing fetus. There is no direct vascular connection between the mother and the
umbilical cord of the fetus. (B) A second mode of transfer starts at the end of the 1st trimester. The SYS and two-thirds of the placental
mass degenerate and the ECC is progressively obliterated by the growing AC containing the amniotic fluid (AF) surrounding the fetus.
These major anatomical transformations modify considerably the spatial relationships between maternal tissue and developing fetus,
and, consequently, the maternal–fetal exchange pathways. From 11–12 weeks onwards maternal nutrients, including thyroid hormone,
are transferred from the placenta directly into the fetal circulation. The AF contains fetal urine and waste products. U, uterus; UC,
umbilical cord; CL, chorion laeve (membranes in development).
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maternal serum, with T3 being even lower. The new
finding was that this great difference between the
maternal and fetal concentrations of total T4 might
be misleading with respect to their potential biological
significance, because the proportion of T4 that is not
bound to proteins is so much higher than in adult
sera that the concentrations of T4 actually ‘available’
to developing tissues, namely those of FT4, reach
values which are comparable to those known to be
biologically active in their mothers (Fig. 2B).
The FT4 levels in the fetal fluids are defined by the
concentrations of T4-binding proteins and the concen-
trations of maternal T4 or FT4 that have escaped the
placental ‘barrier’. The T4-binding capacity of the pro-
teins in fetal fluids is determined ontogenically, is inde-
pendent of the maternal thyroid status, and is far in
excess of the amounts of total T4 that reach the fetal
fluids. Thus, the availability of FT4 for embryonic and
fetal tissues is ultimately determined by the maternal
circulating T4 or FT4 and would decrease in hypothyr-
oxinemic women, even if they are clinically euthyroid.
The results explained why an efficient ‘barrier’ to
maternal thyroid hormone transfer is actually necess-
ary. If total T4 and T3 reached the same concentrations
in fetal fluids as those in the maternal serum, the devel-
oping tissues would be exposed to inappropriately high,
and possibly toxic, concentrations of FT4 and ‘free’ T3
(FT3). An inordinately high FT4 and/or FT3 could
result in adverse effects on the timely sequence of
thyroid hormone-sensitive developmental events in
the human fetus, as recently confirmed (20).
That thyroid hormone-sensitive developmental
events may already occur before midgestation and
onset of FTF is supported by the early presence of
nuclear TRs in the human fetal brain. These were
detected in the earliest samples of the cerebral cortex
(9 weeks PMA) studied by Bernal & Pekonen (15)
with their concentration increasing at least 10-fold by
18 weeks. Despite the very low fetal serum concen-
trations of T3, the occupation of the TRs by this
iodothyronine was 25–30% throughout the study
period (15–17), strongly suggesting that biological
effects of the hormone might already be occurring in
the cerebral cortex during the first trimester of
human pregnancy. A recent study (21) has confirmed
the early expression of TR gene isoforms and related
splice variants in the whole fetal brain studied between
8.1 and 13.9 weeks PMA. Expression of the TRb1,
TRra1 and c-erbAa2 isoforms was detected in the 8.1
week brain sample, with TRa1 being the predominant
form in early development, increasing steadily up to
13.9 weeks; so did the c-erbAa2 isoform. TRb1
expression appeared to present a more complex onto-
genic pattern. The authors moreover point out that
the repressor activity of un-liganded Tra1 on basal
gene transcription may also become relevant when
the maternal supply of hormone decreases: a decrease
in the amount of T3 available for receptor binding
Figure 2 (A) Changes in concentrations of total T4 and FT4 in
fetal fluids up to midgestation, as a function of maternal serum T4
values, which were within the normal range (18). (B) Concen-
trations of total and FT4, as a function of postmenstrual age, in
fetal coelomic fluid (CF), amniotic fluid (AF), fetal blood (F-B) and
maternal blood (M-B). The ordinates in both panels are on a
logarithmic scale, in order to better visualize the similarity of the
FT4 concentrations in fetal fluids to those in the corresponding
mother, whereas there is a greater than 100-fold difference in the
T4 concentrations (data from (19)). For both (A) and (B) the fetal
fluids were obtained without severing maternal to fetal vascular
connections.
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would increase the proportion of the un-liganded iso-
form and its repressor activity, and further interfere
with thyroid hormone-sensitive biological effects.
The ontogenic patterns of the concentrations of T4,
T3, rT3, and of D1, D2 and D3 activities have now
been studied (22) in nine different cerebral areas from
fetuses of 13–20 weeks PMA, when fetal serum T4
increased significantly from about 3 to 15 pmol/ml,
whereas T3 did not correlate with PMA and remained
at about 0.5 pmol/ml throughout the same develop-
mental period (19). The ontogenic profiles of the
concentrations of the iodothyronines in the different
areas of the brain, and of their D2 and D3 activities,
showed both spatial and temporal specificity, but with
divergence in the cerebral cortex as compared with
other brain areas (Fig. 3). In the cortex the concentration
of T4 was increasing with PMA, as expected from
the increase in fetal serum T4. But, in contrast with
the very low and practically constant circulating levels,
T3 increased significantly with PMA in the cortex
between 13 and 20 weeks PMA to levels comparable to
those reported in adults (2.5 pmol/g). These findings
show that in the human cerebral cortex T3 is also gener-
ated locally from T4, and is hardly influenced by
circulating T3. Considerable D2 activity was indeed
found in the human cerebral cortex, whereas D3 activity
was very low. In contrast, cerebellar D3 activities were
very high until midgestation, and T3 was very low,
only increasing after midgestation, when D3 activity
was decreasing. Other regions with high D3 activities
(midbrain, basal ganglia, brain stem, spinal cord,
hippocampus) also had lowT3 concentrations up tomid-
gestation. The study (22) supports the hypothesis that
T3 is indeed required by the human cerebral cortex
before midgestation, when the mother is the only
source of the FT4 that is available to the fetal tissues. It
confirms the important roles of D2 and D3 in the local
bioavailability of cerebral T3 during fetal life; D2 gener-
ates T3 from T4 and D3 protects different brain regions
from an untimely, or excessive, T3 until this hormone
is required for differentiation.
We do not, however, have precise information on
the stage of human brain development when down-
regulation of D2 expression and/or activity might
contribute to T3 bioavailability in conditions of
maternal or fetal hypothyroxinemia; if down-regulation
is delayed with respect to the onset of its expression, a
decrease in maternal T4 would ultimately result in a
lower intracellular concentration of T3 (4).
Between midgestation and birth
There is a dearth of information on the ontogenic
patterns of thyroid hormone concentrations and
iodothyronine deiodinase expression and/or activities
in different fetal tissues during the second half of
pregnancy. Studies performed so far have relied on
autopsy material of babies who died of different
causes and at variable intervals after a premature
birth, and results are subject to many confounding fac-
tors other than their PMA. The most important ones
are likely to be the premature interruption of the
Figure 3 Ontogenic changes in the concentrations of T4 (upper panels), and T3 (lower panels) in the human cerebral cortex (left-hand
panels) and cerebellum (right-hand panels) up to midgestation when the mother is the only source of thyroid hormone for the developing
fetus (data from (22)). During this period T4 in the fetal serum increases about 5-fold, from 3 to 15 pmol/ml, whereas circulating T3
remains very low, about 0.5 pmol/ml (equivalent to 0.5 pmol/g), and does not increase with PMA (19). D3 activities are very high in the
cerebellum throughout this period.
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maternal supply of T4 and the sudden major decrease
in circulating thyrotropin (TSH). For this reason such
studies will not be included here. We will only summar-
ize what is known regarding thyroid hormones and
related indices of fetal thyroid physiology that have
been obtained in utero and in vivo, restricting our
knowledge to data obtained from serum samples.
For many years most diagrams (23) describing onto-
genic patterns of changes in fetal circulating levels of
T4, T3, rT3, TSH, T4-binding globulin (TBG) etc. had
been derived from premature babies, after interruption
of maternal connections. Early in the 1990s, however,
ultrasound-guided blood sampling from the umbilical
cord and the heart was used to obtain fetal samples
between 12 and 37 weeks PMA (24, 25) (Fig. 4). Some
of the patterns previously described (23) for different par-
ameters of FTF were confirmed: T3 and FT3 were very
low throughout fetal life, as compared with those in
both the maternal serum and in the adult population.
In striking contrast, however, both T4 and FT4 increased
steadily with fetal age, and reached maternal and adult
concentrations by the beginning of the third trimester
(25). Contrasting with previous reports of a negative
feed-back between the fetal thyroid and the hypothala-
mic–pituitary system during the third trimester,
Thorpe-Beeston et al. (25) found that FT4 and TSH
were both increasing until birth.
An even greater discrepancy concerned the intrau-
terine fetal levels of TSH that were much higher than
maternal and adult values throughout the study
period, a finding confirmed in our later study (19).
This was in conceptual agreement with reports that in
both normal and anencephalic fetuses, TSH bioactivity
is greatly increased with respect to that circulating in
the mothers, confirming that fetal serum TSH is neither
of maternal origin, under hypothalamic neuroendo-
crine control, nor under negative feed-back control by
thyroid hormones, whether of maternal or fetal origin
(26). Fetal TSH levels are already high well before full
maturation of hypothalamic–pituitary connections at
midgestation. This poses unanswered questions regard-
ing its origin; synthesis of TSH by the rat and monkey
brain have been reported (27). More recently, a TSH
receptor has been found in early human fetal brain
and human astrocytes in primary culture (28). This
receptor mediates extrathyroidal cAMP-independent
biological effects of TSH, among which is, quite inter-
estingly, the stimulation of D2 in astroglial cells. The
possible cAMP-independent ‘extrathyroidal’ actions of
TSH throughout human fetal development are most
intriguing, especially if acting in brain development as
a growth factor. Equally intriguing is why the high
intrauterine TSH concentrations plummet with birth.
Sudden severance from the placenta might be playing
a role, as the placenta produces high amounts of
thyrotropin-releasing hormone-like peptides that
might be stimulating extrapituitary synthesis of TSH
or TSH-like proteins.
Fetal circulating T4 and FT4 are already increasing
steadily in utero before the fetal thyroid is likely to be
able to maintain such concentrations when deprived
Figure 4 (A–C) The ontogenic changes in different parameters
of thyroid hormone status from 12 weeks PMA until birth,
obtained in vivo by cordocentesis, without interfering with the
normal connections between mother and conceptus. The
shaded areas enclose the values reported by Thorpe-Beeston
et al. (25). (A and B) Show that fetal serum FT4 values reach
maternal concentrations shortly after midgestation, whereas
those of FT3 are low throughout pregnancy. (C) Draws attention
to the very high levels of fetal TSH, most of which were higher
than those of the mother. (A) Also shows the FT4 levels found
in sera from premature babies (B, preterm) (30, 31) as com-
pared with those in utero (25).
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of the maternal contribution; the degree of iodination
of thyroglobulin (Tg) and its T4 and T3 contents are
very poor before 42 weeks PMA (29). This lack of full
maturation of the fetal thyroid would contribute signifi-
cantly to the neonatal hypothyroxinemia of premature
infants, a possibility that is strongly supported when
serum FT4 concentrations of such infants are plotted
as a function of PMA and superimposed on the pattern
found for age-paired living fetuses that are still in utero
(Fig. 4) (30, 31). Such observations imply that the
mother continues to contribute significantly to fetal
circulating T4 and FT4 until birth, as described for
experimental animals.
That the transfer of maternal T4 to the fetus con-
tinues until the umbilical cord is severed was conclus-
ively shown in 1989 by Vulsma et al. (5) who found
concentrations of T4 in cord blood of seven neonates
with complete organification defect, namely, a complete
inability to iodinate proteins and, therefore, to syn-
thesize the iodinated hormones. These concentrations
varied between 35 and 70nmol/l, values that are
about 30–60% of the mean concentrations reached
by the normal fetus at term, 109nmol/l (25). In
hypothyroid rat fetuses, serum T4 concentrations
ranging between 30 and 60% of normal, together
with the compensatory increase of D2 activity in the
brain, would be enough to preferentially avoid cerebral
T3 deficiency (6). Extrapolation of the latter findings to
the human CH fetus suggests that after midgestation
the down-regulation of cerebral D2 is also operative
in the human brain, and has contributed to protect it
from major CNS damage until birth.
Summarizing
Results so far confirm for the human developing brain
the same principles that appear to modulate T3
bioavailability in different developing structures in
many species, in a temporally and spatially specific
sequence of events, namely by the ontogenetically pro-
grammed expression of the iodothyronine deiodinase iso-
enzymes, mainly D2 and D3. We have less information
regarding mechanisms other than those involving the
iodothyronine deiodinase isoforms that might also play
important roles in tailoring T3 bioavailability to chan-
ging needs of developing human brain structures.
Thus, both T4 and T3 are present in human
embryonic and fetal fluids, with the FT4 reaching
concentrations that are known to be biologically rel-
evant in adults. The FT4 concentrations in these
fluids are, moreover, directly dependent on the
maternal T4 supply, and so is the FT4 available to
fetal tissues, including the brain. It appears plausible
to conclude that the lower the maternal T4 early in
pregnancy, the lower the FT4 available to the fetal
cortex and, presumably, the lower the amounts of T3
available for binding to cerebral TRs exerting biological
effects. It is important to realize that this could already
occur with maternal circulating levels that are still
within the normal reference range for adults (Fig. 2).
Although valuable new insights have been obtained
regarding the ontogenic patterns of change of cerebral
thyroid hormone concentrations, their nuclear recep-
tors, and the roles of the deiodinating isoenzymes in
tailoring the bioavailability of T3 to the developmental
requirements of different cerebral structures, it is likely
that we are still quite far from understanding all the
mechanisms that may be involved, and their inter-
relationships. As summarized recently in somewhat
more detail (4), little is known regarding the roles, in
determining the availability of circulating T4 to the
fetal brain, of the activities of the deiodinating enzyme
isoforms in other fetal tissues, as well as those of the sul-
fotransferases, glucuronidases and sulfatases, and of
recently identified specific iodothyronine plasma mem-
brane transporters into, and out of, the fetal brain.
We have already remarked (4) upon our ignorance
with respect to a possible developmental role of the
high levels of TSH throughout gestation, as well as
the cause for their rapid decrease after premature
birth. We still have insufficient information regarding
the capacity of the fetal thyroid to meet the needs of the
newborn preterm infant faced with the untimely inter-
ruption of the maternal supply of hormone. Mainly
for this reason, effective procedures that might
improve their neurodevelopment have not yet been
fully established (32).
Direct evidence of a role of maternal T4
in neurogenesis
Present findings regarding regulatory mechanisms
involved in the bioavailability of T3 in the human
fetal cortex early in development, as well as the early
expression of nuclear TRs, already occupied by T3,
strongly support the hypothesis that an adequate
supply of maternal T4 is already needed by the cerebral
cortex early in pregnancy. In man, such an hypothesis
cannot be directly verified, or negated, for obvious ethi-
cal constraints.
In the rat, changes inmaternal thyroid hormone avail-
ability during early stages of development – equivalent to
the end of the first, and beginning of the second, trimester
in man – affect neurogenesis irreversibly. Two models
have been studied so far. One involved iodine-deficient
rat dams (8). The other involved rat dams treated for
only 3 days with a goitrogen (methyl-mercapto-imidazole
(MMI)), a protocol that resulted in a transient and very
mild degree of maternal thyroid hormone deficiency
(3dMMI model) (9). In both models the dams were
hypothyroxinemic between E14 and E16, a period of
very active neurogenesis and of migrations of radial neur-
ons into the developing cerebral cortex and hippocampus,
the mother being the only source of thyroid hormone
available to the developing fetus. The final location of
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the cells generated during this period was aberrant, with
neurons appearing in layers of the somatosensory cortex
and hippocampus where they are never found in pups
from normal dams. The cytoarchitectures of the barrel
cortex and hippocampus were also affected. The short
transient period of moderate maternal thyroid hormone
deficiency between E12 and E15 (3dMMI model) (9) was
sufficient to derange successive radial waves of neuronal
migrations and to result in cytoarchitectural abnormal-
ities that could only be prevented by the timely infusion
of T4. This was of no benefit when delayed beyond the
critical period of corticogenesis. An increased suscepti-
bility to acoustic stimulation was also observed in a high
proportion of the pups born to 3dMMI dams.
Such findings clearly support the importance of an
adequate early supply of maternal thyroid hormone
for neurodevelopment. Extrapolation to man would
define the period in human gestation when the fetal
cerebral cortex is especially sensitive to changes in
the availability of maternal thyroid hormone within
the first half of pregnancy. In man, the two main
waves of radial migrations of neurons into the cortex
peak at 11 and 14 weeks PMA. The first one coincides
approximately with the human chorionic gonadotropin
(hCG)-driven maternal FT4 surge.
Thyroid function of the mother
It has been known for decades that important changes
occur in thyroid hormone physiology during normal
pregnancy. When it was initially observed that
maternal circulating T4 was higher than in non-preg-
nant women, it was believed that this was a direct
consequence of the estrogen-stimulated increase of cir-
culating TBG and of TBG moieties that are more highly
sialylated and have longer biological half-lives.
The increase in circulating T4 was deemed necessary
in order to keep circulating FT4 within the normal
range, but the expected transient decrease in FT4, fol-
lowed by a rise in TSH, necessary to attain the new
equilibrium was not detected.
The transient initial surge of maternal
circulating FT4
We now know that the increases in T4 and TBG do not
occur simultaneously, and FT4 is actually significantly
increased for several weeks before TBG concentrations
plateau at midgestation (33). The increased concen-
trations of hCG in the maternal and fetal compartments
are essential for the maintenance of the pregnancy and
are imposed by the presence of the conceptus. During
this period the woman’s thyroid is under the control of
the high concentrations of hCG and hCG-related
molecules that have TSH-like activity. During early preg-
nancy, when these are highest, secretion of both T4 and
T3 is stimulated to the point that maternal circulating
TSH is suppressed. Plotting mean maternal serum
hCG levels as a function of gestational age shows peak
concentrations at the end of the first trimester,
with TSH levels falling in a mirror image (Fig. 5).
Figure 5 (A) shows that during the first trimester there is an
increase in circulating hCG (A, upper panel) that results in a first
trimester surge of maternal FT4 and FT3 (A, lower panel), and a
suppression of circulating TSH (A, upper panel). These results
support the present hypothesis that the surge in maternal FT4
before midgestation is controlled by the conceptus, and may have
a biologically relevant role, and that an inadequate surge might
not be detected using as the indicator an increase of serum TSH
above the normal population range. Drawn using mean values
reported by Glinoer (33). (B) An example of the effects of the iod-
ine intake on the first trimester FT4 surge and on FT4 values
throughout pregnancy, based on data from a study (46) of preg-
nant women with a median urinary iodine of 90–95mg I/l through-
out gestation, and of those in the same area advised to take
potassium iodide (KI) supplements (approximately 250mg I/day)
from early pregnancy, and a mean urinary iodine excretion double
that of the non-supplemented women. First trimester median FT4
values for non-supplemented and supplemented women were,
respectively, 16.9 and 19.9 pmol/l.
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This phenomenon has even been observed in a case of
thyroid hormone resistance (34); the already high
serum T4 and T3 increased further at the onset of preg-
nancy and reached peak values when circulating hCG
was highest, at 10–12 weeks of gestation, with a
mirror image in serum TSH that was temporarily
suppressed.
This initial adaptation of maternal thyroid physiology
to the presence of the fetus may well be one more
example of the control exerted by the conceptus on the
maternal endocrine system. One possible interpretation
is that it is essential for the conceptus to ensure, for its
own benefit, high maternal FT4 concentrations that
are relevant for early neurodevelopment. To achieve
this, it would be necessary to transiently override the
control of thyroid function through the negative hypo-
thalamic–pituitary–thyroid feed-back mechanism.
Increased production of T4 by the maternal
thyroid Maternal thyroid hormone production
during the first half of human pregnancy obviously
has to increase very soon after its onset, in order to
ensure the early surge in circulating FT4, considering,
among other factors, that the plasma volume increases
rapidly. There is also an increased degradation of the
iodothyronines by the very high activity of D3 in the
uterine–placental unit, possibly also a consequence of
the increased estrogen levels (12). The increase in
the size of the maternal T4 pool early in pregnancy
has not yet been defined precisely, and may differ in
different pregnancies of the same woman. Available
information suggests that it imposes a considerable
burden on the maternal thyroid. It has been known
for years that hypothyroid women very often have to
increase their T4 dose during pregnancy (35) to ‘nor-
malize their TSH’, the standard goal of treatment for
non-pregnant patients. A very recent study (36)
has drawn attention to the need for increasing the
levothyroxine dose already by the fifth week of gestation
by about 50%, in order to keep TSH within the normal
range. This early and significant increase of the T4
dose, however, failed to reproduce the first trimester
FT4 peak and TSH nadir found in normal pregnant
women. An even greater increase in the dose might
have been required if the aim had been attainment of
the physiological trimester-specific FT4 and TSH
values (37). This possibility is in conceptual agreement
with the marked increase in iodine requirements (38,
39), which almost double from the onset of pregnancy,
and is not entirely explained by the increased renal
iodide clearance.
Conditions required for the maternal thyroid
to meet the demands imposed by the conceptus
There are two principal requisites for the maternal
thyroid to be able to meet the burden imposed by
the conceptus, namely (i) that thyroid tissue is not
functionally impaired, and (ii) that the supply of iodine
for the synthesis of sufficient T4 is almost double. It is
becoming increasingly evident that the frequency with
which women from Western industrialized countries
might not be able to respond adequately to the greatly
increased demands of T4 placed by the presence of the
conceptus, is a 100-fold greater, or more, than that of
CH babies, whose detection and early treatment by
mass screening programs have proved so successful.
Impaired thyroid function In a recent summary by
Glinoer & Smallridge (39) on ‘The impact of Maternal
Thyroid Disease on the Developing Fetus: Implications
for Diagnosis, Treatment and Screening’, four different
conditions were discussed from a practical point of
view: (i) clinical hypothyroidism, with low serum FT4
and high serum TSH; (ii) subclinical hypothyroidism,
with normal FT4 and high TSH; (iii) thyroid autoimmu-
nity features, with normal FT4, normal TSH with thyr-
oid antibodies; and hypothyroxinemia with low FT4 and
normal TSH, and (iv) hypothyroxinemia with low FT4
and normal TSH, and clinical euthyroidism.
From North-American and Western European evalu-
ations, up to 0.5% of pregnant women (1 in 200) may
have overt hypothyroidism and up to 2.5% of them
(1 in 40) subclinical hypothyroidism, undetected
before pregnancy. With respect to the third condition,
between 6 and 12% of women of child-bearing age
(1 in 16 to 1 in 8) may have thyroid antibodies, with
strictly normal FT4 and TSH. Most of these reports
relied on an upper limit for ‘normal’ TSH of approxi-
mately 5mU/l. The number of women diagnosed as
clinically or subclinically hypothyroid would probably
increase further if the newer upper limit of 2.5mU
TSH/l were used, and even more if first trimester-
specific ranges of serum FT4 and TSH values were
available (37). Our present drawback is that we still
lack reliable basic information regarding appropriate
trimester-specific reference ranges for FT4, T4 and
TSH obtained with samples from normal pregnancies
in euthyroid women with a confirmed appropriate
iodine intake (250mg I/day) and without autoimmune
disease (2, 35, 37).
Maternal hypothyroxinemia Of the four conditions
indicated above, maternal hypothyroxinemia is the
most frequent, even in industrialized Western societies.
In The Netherlands, a population considered as iodine-
sufficient, neurodevelopmental deficits have been
reported (40) in one out of every two offspring from
womenwith first trimester FT4 below the10th percentile
(1 in 20 births). The etiology of the maternal hypothyr-
oxinemia reported in these studies has not been clarified.
The maternal hypothyroxinemia that is caused by an
iodine intake that fails to meet the increased needs
imposed by the conceptus, is likely to be much more fre-
quent than primary thyroid failure and thyroid autoim-
munity. It has been amply documented that iodine
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deficiency is, worldwide, the most frequent cause of
reproductive failure, decreased mental and motor func-
tions, and cerebral palsy (41–43). Neurodevelopmental
deficits not only occur in areas of severe iodine
deficiency, more recent findings show that even mild
degrees of iodine deficiency are potentially adverse for
the outcome of pregnancy (38, 42, 44). A very recent
10-year follow up (45) of the progeny of women with
mild iodine deficiency has shown an unusually high
proportion (70%) of children with attention deficit
hyperactivity disorders among those born to mothers
who had been hypothyroxinemic during the first half
of pregnancy. This, superimposed on the decrease,
albeit moderate, of their intelligence quotients, constitu-
tes an important handicap in our increasingly competi-
tive societies. A recently published study (4) reveals that
as many as 25% of pregnant women in the United States
have iodine intakes that are less than half those
recommended during pregnancy. Higher frequencies of
this pregnancy-related iodine insufficiency are being
reported from Western European populations where
schoolchildren and non-pregnant women have an
adequate iodine intake (3, 10, 39, 46, 47).
Remarks regarding maternal
hypothyroxinemia caused by iodine
deficiency
Why is this condition, potentially the most frequent
preventable cause of learning disabilities in our indus-
trialized societies, receiving so little attention in medical
practice? We should like to point out a few of the poss-
ible reasons.
Unchanged serum TSH
Regulation of thyroid function through the hypothala-
mic–pituitary–thyroid negative feed-back is so
ingrained in our thinking, that a low T4 is automatic-
ally associated with a high TSH. Thus, the definition
of hypothyroxinemia itself – a decreased T4 without
an increase of TSH above normal – is instinctively
rejected. Very efficient mechanisms controlling thyroid
function – other than the negative feed-back – are over-
looked by, or are even unknown to, most physicians.
More than half a century ago it was shown that the
immediate response of the gland to decreased circulat-
ing iodide triggers very efficient autoregulatory mech-
anisms that result, among others, in an increase in
thyroid vascularity, iodine uptake, acinar cell height,
hyperplasia and serum T3/T4 ratios. All these changes
are independent from TSH, and occur even when hypo-
physectomized rats, or hypophysectomized animals on
TSH substitution, are fed a diet low in iodine (48–50).
Their autonomy from TSH in man has recently been
confirmed (51). Among the many changes that occur,
one directly related to the present topic regarding
maternal hypothyroxinemia is that the synthesis and
secretion of thyroid hormones is switched towards a pre-
ferential use of the decreasing iodine supply in favor of
T3 over T4 (50, 52). As a consequence, circulating T4
decreases, but T3 does not, and may actually increase,
preventing both an increase in serum TSH and clinical
manifestations of hypothyroidism (53–55). Indeed,
increased serum TSH is rarely found in goitrous individ-
uals from areas with iodine deficiency alone, with
increased Tg concentrations being a much more fre-
quent finding in mild to moderate iodine deficiency. In
the seminal studies by Glinoer and colleagues (10, 33,
56) on thyroid function in pregnant women from a
population with moderate iodine deficiency, increased
TSH levels were not found, even among the women
with the lowest first trimester FT4 levels, whereas
increased T3/T4 molar ratios and serum Tg, were
already observed from the onset. Serum TSH tended to
increase by the third trimester, but mostly remained
within the normal range.
The generalized, but inaccurate idea that iodine
deficiency not only lowers T4 production, but results
necessarily in increased circulating TSH is mostly
derived from studies in iodine-deficient areas where
additional factors (i.e. goitrogens, selenium deficiency,
etc.) result in loss of functional thyroid tissue, and
even in glandular atrophy (57, 58), curtailing adap-
tation through autoregulatory mechanisms.
Maintenance of euthyroidism
Iodine deficiency is also inaccurately associated with
clinical manifestations of hypothyroidism; individuals
are frequently referred to as hypothyroid, even in
recent reviews (i.e. see (59) and keywords in (33)).
This statement is correct in individuals from the same
iodine-deficiency goiter endemias with myxoedema indi-
cated above where TSH is increased. This widespread
assumption has been inadvertently compounded by
the inclusion of ‘hypothyroidism’ in the long list of
IDDs that summarized findings from areas with endemic
goiter (60). No distinction was made between IDDs
reported from areas of iodine deficiency alone from
those reported from areas where additional factors
result in loss of functional thyroid tissue. Individuals
from areas where the autoregulatory mechanism
permit their adaptation to the inadequate iodine
supply, are clinically euthyroid, even in situations of
severe iodine deficiency (53) because of their normal,
or increased, circulating T3.
To further complicate the issue, tissues (such as the
brain) that depend mostly on T4 for their availability
of T3 may, however, be T3-deficient and selectively
hypothyroid (60) without clinical manifestation of
hypothyroidism of the individual as a whole. They are
often described as ‘dull’, with whole populations
appearing to ‘wake up’ when the iodine deficiency –
and the hypothyroxinemia – are corrected (61).
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Maternal vs fetal adaptation to iodine
deficiency
The fetus constitutes an exception with respect to our
previous comments regarding the unchanged serum
TSH and the clinical euthyroidism of inhabitants of
areas with iodine deficiency alone, because autoregula-
tory mechanisms are not yet fully operative until after
birth (62); there would be no preferential secretion of
T3 preventing an increase in serum TSH and hypothyr-
oidism. This is in conceptual agreement with the obser-
vation that the proportion of newborns at screening
with whole blood TSH above 5mU/l is increased above
3% in populations with iodine deficiency (51). For the
same reason, they would not be protected from
hypothyroidism. Statements pertaining to the thyroid
status of the mother should be dissociated from
those regarding the fetus, as they are not necessarily
the same.
Final comments
Presently available information that has been summar-
ized here supports the hypothesis that an inappropriate
first trimester surge in maternal FT4, whatever the cir-
culating TSH, would interfere with the development of
the cerebral cortex, even if maternal euthyroidism is
maintained by normal circulating T3 (Fig. 6).
There is at present increasing consensus that
maternal hypothyroidism, both clinical and subclinical,
requires early detection and prompt treatment, because
of its important negative effects for the woman, the preg-
nancy and the child (i.e. see (1, 2, 4, 10, 35, 39, 59)).
Their early detection, and that of women with thyroid
autoimmunity, by mass screening programs poses con-
siderable logistic problems in large countries such as
the United States, but ought to be implemented in Euro-
pean countries already providing special health care for
pregnantwomen, without further controlled prospective
trials regarding the efficacy of treatment, which might
no longer be ethically acceptable. With respect to mass
screening for maternal hypothyroxinemia, the most
frequent cause of preventable neurodevelopmental
handicaps, there are still uncertainties regarding the
cut-off points of laboratory data for its definition. This is
the bad news. But the good news is that most cases of
maternal hypothyroxinemia are related to a relative
iodine deficiency during pregnancy that can be so
easily prevented, with minimal expense, without risk
(63) and with worldwide success (38, 41). It follows
that we can already prevent a very frequent cause of
learning disabilities of new generations by promoting:
(i) the use of iodized salt throughout life, possibly by
universal salt iodization (41); and (ii) the use of iodine
supplements, both as vitamin–mineral mixtures that
contain potassium iodide, or as potassium iodide tablets,
where available, from the onset of pregnancy – or earlier
if pregnancy is planned – just as folate supplements are
extensively promoted, whether or not folate deficiency is
confirmed.
In the early 1920s, David Marine, a precursor of
present programs for the worldwide elimination of
IDDs expressed his views that ‘simple goiter is the
easiest to prevent of all known diseases. It can be
excluded from the list of human diseases as soon as
society decides to undertake the necessary effort’
Figure 6 Possible timing in man of cerebral developmental events
that are sensitive to maternal thyroid hormones in the rat (9)
(lower panel), with respect to timing of first trimester events in
maternal thyroid physiology controlled by the conceptus, such as
the surge in maternal FT4 (middle panel), despite the suppression
of circulating TSH (upper panel).
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(quoted by Langer (64)). The same may still be said,
more than 80 years later, about most cases of learning
handicaps related to maternal hypothyroxinemia.
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